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Background. Pregnant women are a high-risk group for morbidity and mortality from inﬂuenza. During the current pandemic
of H1N1 inﬂuenza, few cases of H1N1 have been reported in pregnancy. Cases. We report two cases of H1N1 inﬂuenza which
occurred in single institution in the course of one month. The ﬁrst patient developed acute respiratory distress syndrome, required
intubation, and eventually died. The second patient had inﬂuenza H1N1 that did not have any major sequela. Conclusion.H 1 N 1
inﬂuenza in pregnancy can be associated with severe complications. Widespread vaccination, when available, prompt diagnosis,
and adequate treatment with antiviral medications when infection occurs are required.
Copyright © 2009 Dmitry Fridman et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
During seasonal inﬂuenza epidemics, pregnant women con-
stitute a high-risk group for disease-related morbidity and
mortality [1]. During current infection pregnancy, seems
to be a major risk factor of lethal outcome [2]. There are
also reports of an increased risk of miscarriage, birth defect,
and preterm delivery when pregnancy is associated with
inﬂuenza infection [3, 4]. However, much less is known
about pregnancy and novel inﬂuenza A (H1N1).
The ﬁrst lethal case of respiratory infection with H1N1
in an adult in the United States was diagnosed in a pregnant
woman on April 30 [5, 6]. To our knowledge (after reviewing
pubmed, google scholar, and cochrane data base), only two
case series totaling eight patients of H1N1 in pregnancy have
been reported (none of which appeared in the obstetrical
literature), with all suggesting a complicated clinical course
[4–6].
2.Cases
2.1. Patient A. On May 26, 2009, a 27-year old middle-
eastern P0000 at 32 weeks of gestation with no signiﬁcant
past medical history presented complaining of cough with
blood-tinged sputum and fevers for four days. The patient
did not recall any contacts with ill individuals and denied
recent travel. She had been evaluated in the emergency room
two days prior to admission and had been diagnosed with
viral syndrome which had not improved. Her vital signs
were pulse 110, respiratory rate 22, blood pressure 119/74,
and temperature 100.1F, while her oxygen saturation ranged
from93%to96%.Onphysicalexamination,shehadbilateral
ronchi in her lungs. Her white blood count (WBC) was
6.6K/Ul. Her chest X-ray revealed bilateral middle and lower
lobe inﬁltrates consistent with pneumonia. When the patient
was admitted, she started on ceftriaxone and azithromycin.
Her nasal swab was negative for inﬂuenzas both A and B, and
when repeated three days later, it was again negative.
The next day the patient developed acute respiratory
distress syndrome, had diﬃculty breathing, had a respiratory
rate of 22–28, and a temperature of 102.0 her pulse oxygen
saturation declined to 86. Due to the deterioration of her
respiratory functions, she was intubated and transferred
to the ICU. She started on piperacillin-tazobactam and
vancomycin, and on hospital day four, she started on
oseltamivir. On hospital day ﬁve her condition continued to
deteriorate, with her arterial oxygen saturation decreasing
to 88% on 100% FiO2. The patient had previously stated
that a cesarean delivery should be performed only if it
carried no risk for her, and she named her husband as her
health care proxy. When the ICU staﬀ felt she could no
longer be sustained even with hand bagging a decision to
perform, a cesarean section was made in the hope that it
would ameliorate the mother’s condition. After the health2 Infectious Diseases in Obstetrics and Gynecology
care proxy agreed, a cesarean delivery was performed in the
ICU and a female infant weighing 1500g, with Apgar scores
of 1 and 1, was delivered. The newborn died on day one with
evidence of chronic hypoxia. In the postoperative period
the patient’s oxygenation status showed some improvement
but she was still requiring high FiO2 to maintain proper
oxygenation. Over the next days the patient’s condition
remained critical. On hospital day 12 the H1N1 inﬂuenza
nasopharyngeal swab taken on day 3 was reported as positive
by the New York Department of Health (DOH). Ultimately,
17daysafteradmission,duetoherdeterioratingoxygenation
status, sepsis, and progressive ARDS, the decision was made
to transfer the patient to another center for extracorporeal
membrane oxygenation. However, the patient expired 25
days after transfer to that institution. Patients autopsy report
was not available.
2.2. Patient B. The patient was a 29-year old white P1011 at
37 weeks of gestation who presented in early labor with fever,
dry cough, headache, nausea, and vomiting. Her prenatal
course was uneventful. She had a temperature of 102.3,
a respiratory rate of 22, a heart rate of 105, and a pulse
oxygen saturation of 100% in room air. She reported that
herdaughterhadsomerespiratorysymptomsandfeverafew
days earlier. Her lab results were unremarkable, with a white
blood count of 4.9, with 8% lymphocytes.
The patient was having irregular contractions, and her
cervix was 1-2cm open and 70% eﬀaced. The fetal heart
rate was 170 with moderate variability. Chorioamnionitis
was suspected and she was admitted for labor augmentation.
BecauseoftheongoingepidemicofH1N1inthecommunity,
she was isolated with droplet precautions, placed in negative
pressure room, and started on oseltamivir and ampicillin-
clavulanic acid. The patient was augmented with oxytocin
and had an uncomplicated vaginal delivery in 8 hours
of a female infant weighing 3220g, Apgar 9/9. She had
an uneventful postpartum period and was discharged on
postpartum day 2. Nasopharyngeal swab cultures that were
sent on admission were reported as positive for inﬂuenzas A
on the next day, and novel inﬂuenza H1N1 was conﬁrmed by
the DOH. The newborn tested negative for inﬂuenza A and
B by real-time reverse transcription PCR. On her six-week
postpartum visit she was asymptomatic, and the baby was
doing well.
3. Discussion
This series of two patients with novel inﬂuenza A (H1N1)
virus demonstrates the variation in course that the disease
may take in pregnancy. The ﬁrst case was a pregnant
woman with late initiation of antiviral therapy. The patient
rapidly progressed to ARDS despite the fact that all the
supportive measures expired. This is illustrative of the
importance of early initiation of antiviral therapy since
delayed initiation has not been shown to have a salutary
eﬀect on individuals with H1N1. A second case—apparently
a more frequent scenario with mild viral symptoms—was
appropriately managed and had no major sequel. Though
mild cases are undoubtedly underrepresented in our report
(as they are in other ones), it is reasonable to suggest that,
as with seasonal inﬂuenza, pregnant women constitute a
population at risk for morbidity and mortality.
Patients with H1N1 viral infection present with acute
respiratory symptoms—dry cough, sore throat, nasal con-
gestion, and fever. Almost one third of them report contact
with an ill individual on admission [7]. The symptoms are
nonspeciﬁc such that it is not surprising that many patients
later conﬁrmed to have swine ﬂu (including those in our
report), had had their symptoms attributed to the common
cold when they had been seen earlier [5, 6]. The CDC
recommends that clinicians use nasopharyngeal swabs for
rapid detection of antigens for inﬂuenzas A and B in patients
with fever and respiratory symptoms. If an unsubtypable
inﬂuenza A virus infection is found, the specimen should
be sent to a state public health laboratory for additional
testing to identify H1N1 virus using the real-time PCR
technique which is currently recommended for laboratory
conﬁrmation of H1N1 viral infection [8]. Antiviral therapy
is often delayed for pregnant patients [4–7], as it was in our
case,anditshouldbereinforcedthatantiviraltherapyshould
be started as soon as possible based only on clinical presen-
tation of fever and sore throat or cough without waiting to
obtain results of laboratory testing, unless another cause of
symptoms is reasonably suspected [9]. It is preferable to start
antiviraltherapywithin48hoursoftheﬁrstinﬂuenza-related
symptoms and continue for 5 days. H1N1 virus is sensitive
to both oseltamivir (75mg twice a day) and zanamivir
(two 5mg inhalations twice a day) [10]. Due to systemic
absorption and more experience with oseltamivir, it is the
preferred medication. The beneﬁt of treating the inﬂuenza
outweighs any theoretical risk for the fetus. In addition
to an antiviral preparation, acetaminophen should also be
started because fever may be associated with neural tube
defect, neonatal seizures, encephalopathy, cerebral palsy, and
neonatal death [3, 9]. It is recommended to treat severe cases
of H1N1 infection in a hospital, using respiratory support
with supplemental oxygen and mechanical ventilation as
required. Antibiotic supplementation should be guided by
the presence of pneumonia depending on the patterns of
resistance in the region [11]. Since pneumococcal pneumo-
nia is frequently a secondary invader, pregnant women who
are in risk groups should also be vaccinated against that
organism.
Current CDC recommendation suggests that pregnant
women who had contact with someone suspected of
infection with novel H1N1 inﬂuenza virus should receive
prophylactic treatment with either oseltamivir (75mg daily)
or zanamivir (two 5mg inhalations daily) for 10 days. The
CDC states that zanamivir is preferable due to its low
systemic absorption, but because of its inhaled route of
administration, respiratory complications must be consid-
ered [9]. H1N1 vaccine is planned to be available by mid-
October, produced in a similar fashion as that of the seasonal
vaccine. The advisory committee on immunization safety
recommends that pregnant women be included in primary
targeted groups for vaccination [12]. Vaccination is also
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however, chemoprophylaxis is not indicated for otherwise
healthy people exposed to inﬂuenza. Early empiric treatment
should be started if symptoms arise [13].
Currently all subtyped inﬂuenza A viruses reported to
CDC (99% of all specimens sent to CDC) are H1N1 [14].
Obstetricians should be prepared to diagnose and rapidly
treat H1N1 and, now with the availability of H1N1 vaccine,
to be proactive with vaccination programs to blunt the
spread of the infection.
Addendum. Since this article was initially submitted, two
additional patients with H1N1, including one who ended up
on ECMO and the other in the ICU, have been cared for at
our facility.
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